Pharmacist Standard of Care Podcast 45 credit minutes

The condition long known as polycystic ovary syndrome (PCOS) has been renamed polyendocrine metabolic ovarian syndrome (PMOS) to better reflect its complex endocrine, metabolic, reproductive, and mental health effects. The name change highlights a growing recognition that this condition extends far beyond ovarian findings and requires a more comprehensive approach to diagnosis, treatment, and long-term risk management. You will be better prepared to understand the rationale behind the new terminology and support patients through evidence-based management of this multifaceted condition. 

Learning Objectives

1. Describe the rationale for the transition from polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS).

2. Explain the endocrine, metabolic, and reproductive features that influence the management of PMOS. 

Faculty

Rachel Maynard, PharmD

Disclosures:

Rachel Maynard has no relevant financial relationships with ineligible companies to disclose

Erin Raney, PharmD, BCPS, BC-ADM

Disclosures:

Erin Raney has no relevant financial relationships with ineligible companies to disclose

Course Details